戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s Utilizing Revascularization and Aggressive Drug Evaluation).
2 inding to develop a platform for preclinical drug evaluation.
3 nd demonstrate the potential of hiPSC-CMs in drug evaluation.
4 ZAN is suitable for application in nicotinic drug evaluation.
5 or the development of therapeutic agents and drug evaluation.
6 the xenograft growth, sample collection, and drug evaluation.
7  one of these Nf1 GEM models for preclinical drug evaluation.
8 te significantly to preclinical and clinical drug evaluation.
9 orally for 6 months, followed by 2-month off-drug evaluation.
10 eans it has much to offer within preclinical drug evaluation.
11 linical models for therapeutic discovery and drug evaluation.
12 ant high-throughput, high-contentscreens and drug evaluation.
13 shed compendia, American Medical Association Drug Evaluations (AMA-DE), United States Pharmacopoeia D
14 technique with a strong potential for use in drug evaluation and development.
15 rious studies in basic biology together with drug evaluation and mechanism of action studies.
16 ed and validated according to the Center for Drug Evaluation and Research (CDER) guidelines.
17                               The Center for Drug Evaluation and Research (CDER) within the US Food a
18 US Food and Drug Administration's Center for Drug Evaluation and Research and MEDLINE for initial app
19 d and Drug Administration's (FDA) Center for Drug Evaluation and Research in 2020.
20                        Within the Center for Drug Evaluation and Research this review team for ophtha
21 , 2004, at a joint meeting of the Center for Drug Evaluation and Research's Psychopharmacologic Drugs
22 shop was cosponsored by the FDA's Center for Drug Evaluation and Research, the Society of Nuclear Med
23 e US Food and Drug Administration Center for Drug Evaluation and Research.
24    This approach can accelerate pre-clinical drug evaluation and system-level brain histology studies
25                 American Medical Association Drug Evaluations and USP-DI subsequently ceased publicat
26 s Utilizing Revascularization and Aggressive Drug Evaluation], BARI 2D [Bypass Angioplasty Revascular
27 de the development of therapeutic agents and drug evaluation by providing molecular level insight int
28 y in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) trial demonstrated that empiri
29 s Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) nuclear substudy compared the
30 s Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) study, which provided optimal
31 s Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial reignited the controvers
32 s Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, some patients with stab
33 e Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, which will be the large
34 s Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
35 s Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE]; NCT00007657).
36 s Utilizing Revascularization and Aggressive Drug Evaluation) diabetes subgroup, (n = 766 of 2,287),
37 y and has the potential to facilitate future drug evaluation for cancers in the central nervous syste
38 dual-modal tracking cell death processes and drug evaluation in a very short time.
39                  Third, we used FASS-LTP for drug evaluation in human synaptosomes.
40 f optimizing in vitro culture conditions for drug evaluation in mycobacteria, a factor which appeared
41                            Italian Agency of Drug Evaluation, Istituto Giannina Gaslini (Genoa, Italy
42 ve anticancer compounds, current preclinical drug evaluations largely fail to satisfy the demand.
43 orts or drug labels issued by the Center for Drug Evaluation, National Medical Products Administratio
44 s Utilizing Revascularization and Aggressive Drug Evaluation; NCT00007657) (Bypass Angioplasty Revasc
45 s Utilizing Revascularization and Aggressive Drug Evaluation; NCT00007657).
46 er to enhance the efficiency of the clinical drug evaluation process and determine rapidly whether a
47 d timing, which are key factors in enhancing drug evaluation processes.
48       Some organ-on-a-chip (OoC) systems for drug evaluation show better predictive capabilities than
49                                        Probe drug evaluations showed bioequivalence (ie, 90% CI of th
50 -nAChRs and the radioligand was suitable for drug evaluation studies.
51 ing post-exposure vaccination strategies and drug evaluation studies.
52                    For preclinical antiviral drug evaluation, the GMP version of the myristoylated pr
53 s Utilizing Revascularization and Aggressive Drug Evaluation) trial according to the presence (+) or
54 s Utilizing Revascularization and Aggressive Drug Evaluation) trial and its effect on risk factors.
55 s Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic st
56 s Utilizing Revascularization and Aggressive Drug Evaluation) trial found similar CV event rates betw
57 s Utilizing Revascularization and Aggressive druG Evaluation) trial randomized 2,287 patients to opti
58 s Utilizing Revascularization and Aggressive Drug Evaluation) trial showed that coronary intervention
59 s Utilizing Revascularization and Aggressive Drug Evaluation) trial, 592 (86%) had complete ascertain
60 s Utilizing Revascularization and Aggressive DruG Evaluation) trial.
61 ed outcomes are increasingly incorporated in drug evaluation trials.
62    We demonstrated a proof-of-concept cancer drug evaluation workflow of potential clinical utility u